The effect of denosumab treatment on muscle strength and muscle mass in patients followed up with osteoporosis

Le résumé fourni par la source

Rationale: We aimed to investigate the effect of denosumab on muscle mass in patients with osteoporosis and under denosumab treatment during the 6-month period. Methods: A total of 84 geriatric outpatients were included. Demographic data, comprehensive geriatric assessment, and anthropometric measurements were performed on all participants. Muscle strength was assessed by handgrip strength, and muscle mass was evaluated on certain muscle groups via muscle ultrasonography (US) and Bioelectrical Impedance Analysis (BIA) before the denosumab treatment and after the 6th month of the treatment. Results: The mean age of the patients was 76.93±7.15 years and 75 % were female. The baseline characteristics of the study population were shown in Table 1. After 6 months of treatment with denosumab, patients had greater muscle mass in lower extremity muscles, rectus abdominis and external oblique muscles according to muscle US (p<0.001 for all). For both sexes, better fat-free muscle mass index was observed after 6 months of therapy, however, HGS has not changed (Table 2).Tabled 1Table 2: Muscle assessments of patients before and after denosumab treatmentBaseline6. monthpMuscle USGastrocnemius Medialis m., mm14.23±2.4914.78±2.51<0.001Gastrocnemius Medialis pennate angle26.66±5.828.32±3.14<0.001Gastrocnemius Medialis, fascicle length, mm28.54±5.2528.61±3.18<0.001Rectus Femoris M., mm14.70±2.7115.23±2.53<0.001Rectus Femoris CsA, cm26.07±1.916.37±1.68<0.001Rectus Abdominis M., mm7.81±1.68.23±1.3<0.001BIAFFMI, kg/m216.90[3.48]17.45[3.23]<0.001Female16.90[3.90]17.40[3.40]<0.001Male17.0[2.40]17.50[3.40]0.021HGS, kg16.8[8.7]16.9[11.0]0.87Female16.2[6.1]16.0[9.0]0.95Male23.0[17.5]23.0[14.23]0.60 Open table in a new tab Conclusion: During the six-month follow-up period, it was observed that patients under denosumab treatment had greater muscle mass according to BIA and Muscle US. References: Liu C. Front Endocrinol (Lausanne). 2022 Disclosure of Interest: None declared

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.